SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity

Phase 2CompletedNCT02819856

Sound Pharmaceuticals, Incorporated35 enrolled

Overview

The primary objective of this study is to determine the safety and efficacy of SPI-1005 treatment in CF patients with active pulmonary exacerbation that are receiving an IV course of tobramycin, determined by comparing hearing assessments, spirometry, Pharmacokinetic (PK), Physical Exam, Adverse Events (AEs) and Labs baseline to post-treatment. The secondary objectives of this study are to determine Pharmacogenomics and Pharmacodynamics of SPI-1005.

Randomized, double-blind, placebo-controlled study to evaluate the safety, and efficacy of SPI-1005 in Cystic Fibrosis patients with Acute Pulmonary Exacerbation receiving intravenous tobramycin at risk for ototoxicity. All patients will undergo baseline testing and have their severity of lung function, sensorineural hearing loss, tinnitus and vertigo determined before the start of SPI-1005 treatment. SPI-1005 treatment will start within first two days of IV tobramycin treatment and be administered concomitantly. At the end of the 21-day course of SPI-1005 and 28 days following the cessation of SPI-1005, patients will have their hearing loss, tinnitus and vertigo reassessed. Assessments may also include additional audiometric and pulmonary testing, and additional follow-up testing.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Ototoxicity

Interventions

PlaceboDRUG

0 mg SPI-1005 bid po x 21d

SPI-1005 Ebselen 200mg Capsule x1DRUG

200 mg SPI-1005 bid po x21d

SPI-1005 Ebselen 200mg Capsule x2DRUG

400 mg SPI-1005 bid po x 21d

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Cystic fibrosis patients about to receive IV tobramycin for acute pulmonary exacerbation. * Voluntarily consent to participate in the study. * Females of childbearing potential should be using and committed to continue using one of the following acceptable birth control methods: * Sexual abstinence (inactivity) for 14 days prior to screening through study completion; or IUD in place for at least 3 months prior to study through study completion; or Barrier method (condom or diaphragm) with spermicide for at least 14 days prior to screening through study completion; or Stable hormonal contraceptive for at least 3 months prior to study through study completion. * Ability to perform all behavioral tests as indicated. Exclusion Criteria: * Current use or within 60 days prior to study enrollment the following IV ototoxic medications: aminoglycoside antibiotics (gentamicin, tobramycin, amikacin, streptomycin); platinum-containing chemotherapies (cisplatin, carboplatin, oxaliplatin); or loop diuretic (furosemide). * History of idiopathic sensorineural hearing loss, otosclerosis, or vestibular schwannoma. * History of middle ear or inner ear surgery. * Current conductive hearing loss or middle ear effusion. * Significant cardiovascular, hepatic, renal, hematologic, endocrine, immunologic, or psychiatric disease. * History of hypersensitivity or idiosyncratic reaction to compounds related to ebselen. * Participation in another investigational drug or device study within 30 days prior to study enrollment. * Female patients who are pregnant or breastfeeding.

Locations (1)

Medical University of South Carolina

Charleston, South Carolina, United States

Outcomes

Primary Outcomes

Sensorineural Hearing Loss Using Pure-tone Audiometry

Number of participants with ototoxicity: Sensorineural hearing loss using pure-tone audiometry according to the American Speech-Language-Hearing Association (ASHA) criteria for ototoxicity.